Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation by Administration of Capadenoson in a Dose of 4 mg Once Daily for Five Days

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00568945

Enrollment

Registered

2007-12-06

Start date

2008-01-31

Completion date

2008-12-31

Last updated

2014-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial Fibrillation, Capadenoson

Brief summary

This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.

Interventions

DRUGCapadenoson (BAY68-4986)

4 mg BAY68-4986 for five days

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Male and/or female (without childbearing potential) white patients * History of persistent or permanent atrial fibrillation * 18 to 75 years of age

Exclusion criteria

* Patients with high-risk cardiovascular diseases * Stroke or myocardial infarction * Relevant pathological changes in the ECG or echocardiography * Medication affecting ventricular response in Afib

Design outcomes

Primary

Measure	Time frame
The effect of capadenoson (BAY68-4986) on rate control in patients with atrial fibrillation	1 week

Secondary

Measure	Time frame
To investigate safety and tolerability of this treatment with capadenoson	2 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026